PI
ATXS

Putnam Investments’s Astria Therapeutics ATXS Stock Holding History

Putnam Investments’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,006
Closed -$741K – 1252
2016
Q3 		$741K Hold
2,006
– – ﹤0.01% 1074
2016
Q2 		$445K Hold
2,006
– – ﹤0.01% 1209
2016
Q1 		$607K Hold
2,006
– – ﹤0.01% 1210
2015
Q4 		$954K Hold
2,006
– – ﹤0.01% 1165
2015
Q3 		$974K Sell
2,006
-463
-19% -$331K ﹤0.01% 1177
2015
Q2 		$1.81M Buy
+2,469
New +$1.87M ﹤0.01% 1093

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Putnam Investments's ATXS Position: Q4 2016 in Review

Putnam Investments sold out of Astria Therapeutics (ATXS) in Q4 2016, closing a stake of 2,006 shares — an estimated $741K sold.

Putnam Investments first reported a position in ATXS in Q2 2015 and held it in 6 quarters. The position peaked at $1.81M in Q2 2015. 26 funds tracked by Wall St. Rank hold ATXS as of Q4 2016.

  • Putnam Investments reported no remaining Astria Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Putnam Investments sold 2,006 Astria Therapeutics shares in Q4 2016, an estimated $741K.
  • Putnam Investments first reported a position in Astria Therapeutics in Q2 2015 and held it in 6 quarters.
  • Putnam Investments's Astria Therapeutics position peaked at $1.81M in Q2 2015.
  • 26 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2016.

Based on Putnam Investments's 13F filing for Q4 2016, filed 14 Feb 2017.